• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[In vitro sensitivity of strict anaerobic Gram-negative bacilli to thienamycin NF and various cephalosporins].

作者信息

Dubreuil L, Devos J, Romond C

出版信息

Pathol Biol (Paris). 1984 May;32(5):429-32.

PMID:6739150
Abstract

Minimal inhibitory concentrations of 105 anaerobic Gram negative bacilli were determined by two-fold dilution in Wilkins - Chalgren agar following the reference method proposed by Sutter et al. No resistance was observed with thienamycin, which is especially active against the Bacteroides fragilis group (MIC 50 = 0.125 mg/l). Among the beta-lactams investigated, cefoxitin and moxalactam proved more active than ceftizoxime and ceftriaxone, while cefotiam exhibited poor activity. While most Fusobacteria were susceptible to studied beta-lactams, some Fusobacterium varium demonstrated resistance to cephalosporins and cephamycins .

摘要

相似文献

1
[In vitro sensitivity of strict anaerobic Gram-negative bacilli to thienamycin NF and various cephalosporins].
Pathol Biol (Paris). 1984 May;32(5):429-32.
2
[Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria].头孢泊肟、头孢呋辛和头孢克洛对严格厌氧菌的抗菌活性比较
Pathol Biol (Paris). 1990 May;38(5):343-6.
3
In vitro activity of imipenem against gram-positive anaerobic bacteria.亚胺培南对革兰氏阳性厌氧菌的体外活性。
Int J Clin Pharmacol Res. 1987;7(1):39-43.
4
In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.N-甲脒硫霉素、噻肟单酰胺菌素及其他新型β-内酰胺类药物对脆弱拟杆菌的体外活性:β-内酰胺酶对耐药性的作用
Antimicrob Agents Chemother. 1981 Feb;19(2):248-52. doi: 10.1128/AAC.19.2.248.
5
Comparative in vitro activities of third-generation cephalosporins.第三代头孢菌素的体外活性比较
Arch Intern Med. 1983 Sep;143(9):1743-5.
6
An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.头孢唑肟及其他头孢菌素/头霉素类抗菌药物对临床重要厌氧菌体外活性的最新研究进展。
Clin Ther. 1990;12 Suppl C:3-12.
7
[In vitro activity of the oxa-beta-lactam LY 127935 against Bacteroides fragilis and other anaerobic gram-negative rods (author's transl)].氧杂β-内酰胺LY 127935对脆弱拟杆菌及其他厌氧革兰氏阴性杆菌的体外活性(作者译)
Infection. 1980;8 Suppl 3:S 342-6.
8
["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].十种抗菌药物对厌氧菌的“体外”活性。一项合作研究,1999 - 2002年
Rev Argent Microbiol. 2004 Jul-Sep;36(3):130-5.
9
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.对包括厄他培南在内的七种抗菌药物针对希腊近期分离出的革兰氏阴性厌氧菌的体外活性进行的多中心调查。
Clin Microbiol Infect. 2005 Oct;11(10):820-4. doi: 10.1111/j.1469-0691.2005.01233.x.
10
In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains.替加环素对希腊近期分离的革兰氏阴性厌氧菌(包括耐甲硝唑菌株)的体外活性。
Diagn Microbiol Infect Dis. 2006 Jul;55(3):231-6. doi: 10.1016/j.diagmicrobio.2006.01.022. Epub 2006 Apr 19.

引用本文的文献

1
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.亚胺培南/西司他丁。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1987 Mar;33(3):183-241. doi: 10.2165/00003495-198733030-00001.
2
Evolution in antibiotic susceptibility of Bacteroides fragilis group strains in France based on periodic surveys.基于定期调查的法国脆弱拟杆菌群菌株抗生素敏感性的演变
Infection. 1989 May-Jun;17(3):197-200. doi: 10.1007/BF01644030.
3
Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992.
1977年至1992年法国脆弱拟杆菌群菌株药敏模式调查。
Eur J Clin Microbiol Infect Dis. 1992 Nov;11(11):1094-9. doi: 10.1007/BF01967804.